{{Rsnum
|rsid=11121380
|Gene=SPSB1
|Chromosome=1
|position=9348900
|Orientation=plus
|GMAF=0.08586
|Gene_s=SPSB1
|Assembly=GRCh38
|GenomeBuild=38.1
|dbSNPBuild=141
|geno1=(A;A)
|geno2=(A;C)
|geno3=(C;C)
}}{{ population diversity
| geno1=(A;A)
| geno2=(A;C)
| geno3=(C;C)
| CEU | 75.2 | 24.8 | 0.0
| HCB | 100.0 | 0.0 | 0.0
| JPT | 100.0 | 0.0 | 0.0
| YRI | 53.7 | 32.0 | 14.3
| ASW | 63.2 | 35.1 | 1.8
| CHB | 100.0 | 0.0 | 0.0
| CHD | 0.0 | 0.0 | 0.0
| GIH | 97.0 | 3.0 | 0.0
| LWK | 67.3 | 30.0 | 2.7
| MEX | 93.1 | 6.9 | 0.0
| MKK | 80.6 | 16.1 | 3.2
| TSI | 81.4 | 18.6 | 0.0
| HapMapRevision=28
}}{{PMID Auto GWAS
|PMID=22491018
|Trait=None
|Title=Genome-wide association analysis implicates the involvement of eight loci with response to tocilizumab for the treatment of rheumatoid arthritis.
|RiskAllele=
|Pval=5E-8
|OR=11.1100
|ORtxt=None
}}

{{on chip | Affy GenomeWide 6}}
{{on chip | HumanOmni1Quad}}